Citizens Jmp Issues Positive Forecast for Lantheus (NASDAQ:LNTH) Stock Price

Lantheus (NASDAQ:LNTH) had its price objective raised by Citizens Jmp from $73.00 to $78.00 in a report issued on Tuesday,Benzinga reports. The firm currently has a market outperform rating on the medical equipment provider’s stock.

Several other research analysts have also recently weighed in on the stock. Weiss Ratings upgraded shares of Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a report on Tuesday, January 6th. Truist Financial lifted their target price on shares of Lantheus from $80.00 to $82.00 and gave the stock a “buy” rating in a research report on Thursday, December 18th. Citigroup restated an “outperform” rating on shares of Lantheus in a research note on Tuesday. Finally, Mizuho increased their price target on Lantheus from $60.00 to $72.00 and gave the company an “outperform” rating in a research report on Wednesday, December 17th. Six investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Lantheus presently has an average rating of “Moderate Buy” and an average target price of $78.83.

Lantheus Price Performance

Shares of NASDAQ:LNTH opened at $73.61 on Tuesday. The company has a current ratio of 2.67, a quick ratio of 2.49 and a debt-to-equity ratio of 0.51. The stock’s fifty day simple moving average is $67.55 and its two-hundred day simple moving average is $59.79. Lantheus has a 1-year low of $47.25 and a 1-year high of $111.29. The stock has a market cap of $4.88 billion, a PE ratio of 30.93 and a beta of -0.08.

Institutional Investors Weigh In On Lantheus

Several large investors have recently added to or reduced their stakes in the company. Hantz Financial Services Inc. lifted its holdings in Lantheus by 412.5% during the third quarter. Hantz Financial Services Inc. now owns 492 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 396 shares during the last quarter. Elevation Point Wealth Partners LLC bought a new stake in shares of Lantheus in the second quarter valued at approximately $26,000. First Horizon Corp bought a new stake in shares of Lantheus in the third quarter valued at approximately $26,000. Smartleaf Asset Management LLC lifted its stake in shares of Lantheus by 63.3% during the 4th quarter. Smartleaf Asset Management LLC now owns 508 shares of the medical equipment provider’s stock valued at $34,000 after buying an additional 197 shares in the last quarter. Finally, Parallel Advisors LLC boosted its holdings in Lantheus by 122.6% in the 4th quarter. Parallel Advisors LLC now owns 541 shares of the medical equipment provider’s stock worth $36,000 after buying an additional 298 shares during the period. Hedge funds and other institutional investors own 99.06% of the company’s stock.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.